Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Peritoneal dialysis solution with dextrose as osmotic agent; removes solutes and water across peritoneal membrane via diffusion and ultrafiltration.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Acute kidney injury requiring peritoneal dialysis
FDA-approved for use as a peritoneal dialysis solution in continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) for patients with acute or chronic renal failure.Off-label: management of fluid overload in patients with heart failure resistant to diuretics (rare).
Intraperitoneal administration: 2 L per exchange, typically 4 exchanges daily (continuous ambulatory peritoneal dialysis). Dextrose 4.25% solution used for ultrafiltration. Dose adjusted based on body size and fluid status.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
None Documented
None Documented
Not applicable as a drug; dextrose is rapidly metabolized; plasma half-life of glucose ~1.5-2 hours; continuous reabsorption in dialysis prevents accumulation.
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Dextrose absorbed systemically and metabolized via glycolysis; lactate buffer converted to bicarbonate in liver.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with some absorption from the peritoneal cavity. Lactate (from the buffer) is metabolized primarily in the liver to bicarbonate.
Peritoneal dialysis; effectively removed via peritoneal membrane during dialysis exchanges; systemic absorption of dextrose minimal; elimination primarily through dialysate outflow; renal excretion negligible in anuria.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Not applicable; dextrose does not bind to plasma proteins.
Dextrose: negligible (<5%); electrolytes: negligible. Peritoneal dialysis solutions per se do not have significant protein binding.
Not applicable; dextrose distributes throughout total body water (~0.55 L/kg); dialysate instilled volume is ~2 L per exchange.
Dextrose distributes in total body water (approximately 0.6 L/kg); for dialysate, distribution into peritoneal cavity volume is 2-3 L.
100% via intraperitoneal route as dialysate; dextrose absorbed systemically at ~10-20 g per exchange depending on dwell time and concentration.
Intraperitoneal: 100% for local effects; systemic absorption of glucose occurs (approximately 60-80% of glucose load) via peritoneal capillaries.
No dose adjustment needed for impaired kidney function as drug is administered intraperitoneally for dialysis; however, monitor serum electrolytes and fluid balance.
Deliver via peritoneal dialysis; no dose adjustment necessary as drug is administered intraperitoneally for renal replacement therapy.
No specific dose adjustment recommended. Caution in severe hepatic impairment due to potential lactic acidosis with dextrose-containing solutions.
No specific dose adjustment; monitor for signs of hepatic encephalopathy or fluid overload in severe hepatic impairment.
Intraperitoneal: 30-40 mL/kg per exchange, up to 1 L per exchange depending on body size; frequency as needed for dialysis. Dextrose concentration tailored to ultrafiltration needs.
Intraperitoneal: 20 to 40 mL/kg per exchange (typical fill volume 800-1100 mL/m2), 4 to 5 exchanges per 24 hours; dwell time 2 to 6 hours per exchange.
Start with lower volumes (e.g., 1.5-2 L per exchange) and monitor for fluid overload and glucose intolerance. Use lowest effective dextrose concentration to minimize hyperglycemia.
No specific dose adjustment; monitor for fluid and electrolyte balance, and adjust dextrose concentration based on ultrafiltration needs and glucose tolerance.
Not for intravenous use.
None.
["Monitor serum electrolytes, glucose, and fluid balance","Risk of peritonitis with catheter use","Hypokalemia or hyperglycemia possible","Not for IV administration"]
Risk of peritonitis, abdominal pain, electrolyte disturbances (e.g., hyperglycemia, hypernatremia, hypokalemia), fluid overload, and metabolic acidosis. Use with caution in patients with severe hyponatremia, hypokalemia, or impaired liver function.
["Pre-existing severe hyperglycemia","Hypersensitivity to any component","Documented loss of peritoneal function","Abdominal conditions compromising dialysis (e.g., recent surgery, adhesions)"]
Hypersensitivity to any component; pre-existing hyperglycemia; severe hyponatremia; hypokalemia; hyperlactatemia; or conditions with increased peritoneal permeability (e.g., peritonitis, severe burns).
Data Pending Review
Data Pending Review
No specific food interactions. However, dietary restrictions typically include limiting sodium, potassium, phosphorus, and fluid intake as recommended by the nephrologist. Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) and high-phosphorus foods (e.g., dairy, nuts, colas) to prevent electrolyte imbalances. Consult a renal dietitian for personalized meal planning.
Dietary restrictions typically include low sodium, low potassium, and low phosphorus intake to manage fluid and electrolyte balance. Avoid high-sugar foods if hyperglycemia develops. Consult a renal dietitian for individualized meal planning.
Delflex w/ Dextrose 4.25% is a peritoneal dialysis solution. No direct fetal risks are expected from the solution itself; however, maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) could affect the fetus. In the first trimester, uncontrolled diabetes may increase the risk of congenital anomalies. In the second and third trimesters, maternal hyperglycemia may lead to fetal macrosomia, neonatal hypoglycemia, and polyhydramnios.
No evidence of teratogenicity in animal studies; human data are lacking. However, in case of severe maternal electrolyte disturbances or infection, potential indirect fetal risks may arise. Generally considered low risk if administered appropriately.
Dextrose and electrolytes from the solution may equilibrate with maternal plasma. Excretion into breast milk is likely minimal and not clinically significant. The M/P ratio is not established; however, the risk to the nursing infant is considered low. Monitoring infant for signs of electrolyte imbalance or hyperglycemia is prudent if maternal serum concentrations are elevated.
Excretion into breast milk is expected to be minimal due to high molecular weight, but specific M/P ratio not reported. Compatible with breastfeeding if maternal therapy is necessary; caution due to possible high glucose load in neonates.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics of components. No specific dose adjustments for Delflex w/ Dextrose 4.25% are established; however, frequent monitoring of maternal glucose and electrolytes is advised to adjust dialysis prescription as needed to maintain metabolic control.
Standard dosing may be used; however, pregnancy-induced hypervolemia and increased glomerular filtration rate may require adjustment of exchange volumes and dextrose concentration to maintain electrolyte and glucose homeostasis. Close monitoring of maternal weight, blood pressure, and serum chemistries is recommended.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% is a peritoneal dialysis solution used in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Monitor for signs of peritonitis, such as cloudy effluent, abdominal pain, and fever. Ensure strict aseptic technique during exchange to prevent infection. The 4.25% dextrose concentration is hypertonic and used for ultrafiltration in fluid overload. Check electrolyte levels regularly, especially potassium and magnesium, as dialysis can alter serum levels. Warm the solution to body temperature before use to improve comfort and dialysis efficiency.
This is a peritoneal dialysis solution containing 3.5% dextrose. Use the lowest dextrose concentration necessary for adequate ultrafiltration to avoid hyperglycemia and metabolic complications. Warm the solution to body temperature before administration to reduce patient discomfort. Monitor serum electrolytes, glucose, and urea regularly. Do not use if solution is discolored or contains particulates.
Wash hands thoroughly before handling the dialysis solution or performing exchanges.Use a clean, dry area for all exchanges and keep the catheter site clean and dry.Inspect the solution bag for cloudiness, leaks, or particulate matter before use; do not use if any are present.Do not reuse or refrigerate the solution; store at room temperature and protect from light.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or cloudy effluent immediately.Follow your prescribed exchange schedule exactly to maintain proper fluid and waste removal.
Store the solution at room temperature and protect from light.Warm the bag to body temperature before use for comfort.Inspect the solution for clarity and discard if cloudy or containing particles.Follow aseptic technique to prevent peritonitis.Report any signs of infection (fever, abdominal pain, cloudy effluent) immediately.